-
1
-
-
4744366279
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
-
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15): 1502-1512, 2004.
-
(2004)
N Engl J Med
, vol.351
, Issue.15
, pp. 1502-1512
-
-
Tannock, I.F.1
De Wit, R.2
Berry, W.R.3
Horti, J.4
Pluzanska, A.5
Chi, K.N.6
Oudard, S.7
Théodore, C.8
James, N.D.9
Turesson, I.10
Rosenthal, M.A.11
Eisenberger, M.A.12
-
2
-
-
75149172293
-
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival
-
Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M and Halabi S: The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 46(3): 517-525, 2010.
-
(2010)
Eur J Cancer
, vol.46
, Issue.3
, pp. 517-525
-
-
Armstrong, A.J.1
Tannock, I.F.2
De Wit, R.3
George, D.J.4
Eisenberger, M.5
Halabi, S.6
-
3
-
-
6044259206
-
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases
-
Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW and Terstappen LW: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10(20): 6897-6904, 2004.
-
(2004)
Clin Cancer Res
, vol.10
, Issue.20
, pp. 6897-6904
-
-
Allard, W.J.1
Matera, J.2
Miller, M.C.3
Repollet, M.4
Connelly, M.C.5
Rao, C.6
Tibbe, A.G.7
Uhr, J.W.8
Terstappen, L.W.9
-
4
-
-
58149165081
-
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer
-
de Bono JS1, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ and Raghavan D: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14(19): 6302-6309. 2008.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.19
, pp. 6302-6309
-
-
De Bono, J.S.1
Scher, H.I.2
Montgomery, R.B.3
Parker, C.4
Miller, M.C.5
Tissing, H.6
Doyle, G.V.7
Terstappen, L.W.8
Pienta, K.J.9
Raghavan, D.10
-
5
-
-
62849099048
-
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: A reanalysis of IMMC38 trial data
-
Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D and Heller G: Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 10(3): 233-239, 2009.
-
(2009)
Lancet Oncol
, vol.10
, Issue.3
, pp. 233-239
-
-
Scher, H.I.1
Jia, X.2
De Bono, J.S.3
Fleisher, M.4
Pienta, K.J.5
Raghavan, D.6
Heller, G.7
-
6
-
-
84880270290
-
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay
-
Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, Klein C, Saini M, Bäuerle T, Wallwiener M, Holland-Letz T, Höfner T, Sprick M, Scharpff M, Marmé F, Sinn HP, Pantel K, Weichert W, Trumpp A: Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31(6): 539-544, 2013.
-
(2013)
Nat Biotechnol
, vol.31
, Issue.6
, pp. 539-544
-
-
Baccelli, I.1
Schneeweiss, A.2
Riethdorf, S.3
Stenzinger, A.4
Schillert, A.5
Vogel, V.6
Klein, C.7
Saini, M.8
Bäuerle, T.9
Wallwiener, M.10
Holland-Letz, T.11
Höfner, T.12
Sprick, M.13
Scharpff, M.14
Marmé, F.15
Sinn, H.P.16
Pantel, K.17
Weichert, W.18
Trumpp, A.19
-
7
-
-
84873811988
-
Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition
-
Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA and Maheswaran S: Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339( 6119): 580-584, 2013.
-
(2013)
Science
, vol.339
, Issue.6119
, pp. 580-584
-
-
Yu, M.1
Bardia, A.2
Wittner, B.S.3
Stott, S.L.4
Smas, M.E.5
Ting, D.T.6
Isakoff, S.J.7
Ciciliano, J.C.8
Wells, M.N.9
Shah, A.M.10
Concannon, K.F.11
Donaldson, M.C.12
Sequist, L.V.13
Brachtel, E.14
Sgroi, D.15
Baselga, J.16
Ramaswamy, S.17
Toner, M.18
Haber, D.A.19
Maheswaran, S.20
more..
-
8
-
-
41949104346
-
Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
-
Scher HI1, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M; Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26( 7): 1148-1159, 2008.
-
(2008)
J Clin Oncol
, vol.26
, Issue.7
, pp. 1148-1159
-
-
Scher, H.I.1
Halabi, S.2
Tannock, I.3
Morris, M.4
Sternberg, C.N.5
Carducci, M.A.6
Eisenberger, M.A.7
Higano, C.8
Bubley, G.J.9
Dreicer, R.10
Petrylak, D.11
Kantoff, P.12
Basch, E.13
Kelly, W.K.14
Figg, W.D.15
Small, E.J.16
Beer, T.M.17
Wilding, G.18
Martin, A.19
Hussain, M.20
more..
-
9
-
-
57849117384
-
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
-
Eisenhauer EA1, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2): 228-247, 2009.
-
(2009)
Eur J Cancer
, vol.45
, Issue.2
, pp. 228-247
-
-
Eisenhauer, E.A.1
Therasse, P.2
Bogaerts, J.3
Schwartz, L.H.4
Sargent, D.5
Ford, R.6
Dancey, J.7
Arbuck, S.8
Gwyther, S.9
Mooney, M.10
Rubinstein, L.11
Shankar, L.12
Dodd, L.13
Kaplan, R.14
Lacombe, D.15
Verweij, J.16
-
10
-
-
50949132840
-
Immunomagnetic quantification of circulating tumors cell as a prognostic factor of androgen-deprivation responsiveness in hormone-naive metastatic prostate cancer patients
-
Okegawa T, Nutahara K and Higashihara E: Immunomagnetic quantification of circulating tumors cell as a prognostic factor of androgen-deprivation responsiveness in hormone-naive metastatic prostate cancer patients. J Urol 180(4): 1342-1347, 2008.
-
(2008)
J Urol
, vol.180
, Issue.4
, pp. 1342-1347
-
-
Okegawa, T.1
Nutahara, K.2
Higashihara, E.3
-
11
-
-
0023834161
-
Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan
-
Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S and Moinuddin M: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61( 1): 195-202, 1998.
-
(1998)
Cancer
, vol.61
, Issue.1
, pp. 195-202
-
-
Soloway, M.S.1
Hardeman, S.W.2
Hickey, D.3
Raymond, J.4
Todd, B.5
Soloway, S.6
Moinuddin, M.7
-
12
-
-
3242742186
-
The natural history of androgen-independent prostate cancer
-
Shulman MJ and Benaim EA: The natural history of androgen-independent prostate cancer. J Urol 172(1): 141-145, 2004.
-
(2004)
J Urol
, vol.172
, Issue.1
, pp. 141-145
-
-
Shulman, M.J.1
Benaim, E.A.2
-
13
-
-
17144426134
-
Circulating tumor cells predict survival in patients with metastatic prostate cancer
-
Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG and Terstappen LW: Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 65(4): 713-718, 2005.
-
(2005)
Urology
, vol.65
, Issue.4
, pp. 713-718
-
-
Moreno, J.G.1
Miller, M.C.2
Gross, S.3
Allard, W.J.4
Gomella, L.G.5
Terstappen, L.W.6
-
14
-
-
37249006715
-
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer
-
Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M and Scher HI: Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13(23): 7053-7058, 2007.
-
(2007)
Clin Cancer Res
, vol.13
, Issue.23
, pp. 7053-7058
-
-
Danila, D.C.1
Heller, G.2
Gignac, G.A.3
Gonzalez-Espinoza, R.4
Anand, A.5
Tanaka, E.6
Lilja, H.7
Schwartz, L.8
Larson, S.9
Fleisher, M.10
Scher, H.I.11
-
15
-
-
15244361321
-
Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease
-
Chen BT, Loberg RD, Neeley CK, O'Hara SM, Gross S, Doyle G, Dunn RL, Kalikin LM and Pienta KJ: Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease. Urology 65(3): 616-621, 2005.
-
(2005)
Urology
, vol.65
, Issue.3
, pp. 616-621
-
-
Chen, B.T.1
Loberg, R.D.2
Neeley, C.K.3
O'Hara, S.M.4
Gross, S.5
Doyle, G.6
Dunn, R.L.7
Kalikin, L.M.8
Pienta, K.J.9
-
16
-
-
58949088650
-
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): A single-centre experience
-
Olmos D, Arkenau HT, Ang JE, Ledaki I, Attard G, Carden CP, Reid AH, A'Hern R, Fong PC, Oomen NB, Molife R, Dearnaley D, Parker C, Terstappen LW, de Bono JS: Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol 20(1): 27-33. 2009.
-
(2009)
Ann Oncol
, vol.20
, Issue.1
, pp. 27-33
-
-
Olmos, D.1
Arkenau, H.T.2
Ang, J.E.3
Ledaki, I.4
Attard, G.5
Carden, C.P.6
Reid, A.H.7
A'Hern, R.8
Fong, P.C.9
Oomen, N.B.10
Molife, R.11
Dearnaley, D.12
Parker, C.13
Terstappen, L.W.14
De Bono, J.S.15
-
17
-
-
59349109415
-
Prognostic significance of circulating tumor cells in patients with hormone-refractory prostate cancer
-
Okegawa T, Nutahara K and Higashihara E: Prognostic significance of circulating tumor cells in patients with hormone-refractory prostate cancer. J Urol 181(3): 1091-1097, 2009.
-
(2009)
J Urol
, vol.181
, Issue.3
, pp. 1091-1097
-
-
Okegawa, T.1
Nutahara, K.2
Higashihara, E.3
-
18
-
-
84901951930
-
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: A phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer
-
Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Datar RH, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Thompson IM Jr., Cote RJ, Vogelzang NJ: Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: A phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32(11): 1136-1142, 2014.
-
(2014)
J Clin Oncol
, vol.32
, Issue.11
, pp. 1136-1142
-
-
Goldkorn, A.1
Ely, B.2
Quinn, D.I.3
Tangen, C.M.4
Fink, L.M.5
Xu, T.6
Twardowski, P.7
Van Veldhuizen, P.J.8
Agarwal, N.9
Carducci, M.A.10
Monk, J.P.11
Datar, R.H.12
Garzotto, M.13
Mack, P.C.14
Lara, P.15
Higano, C.S.16
Hussain, M.17
Thompson, I.M.18
Cote, R.J.19
Vogelzang, N.J.20
more..
-
19
-
-
79959269553
-
Circulating tumor cells as biomarkers in prostate cancer
-
Danila DC, Fleisher M, Scher HI: Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 17(12): 3903-3912, 2011.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.12
, pp. 3903-3912
-
-
Danila, D.C.1
Fleisher, M.2
Scher, H.I.3
-
20
-
-
80053299958
-
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate
-
Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M and Scher HI: TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol 60( 5): 897-904, 2011.
-
(2011)
Eur Urol
, vol.60
, Issue.5
, pp. 897-904
-
-
Danila, D.C.1
Anand, A.2
Sung, C.C.3
Heller, G.4
Leversha, M.A.5
Cao, L.6
Lilja, H.7
Molina, A.8
Sawyers, C.L.9
Fleisher, M.10
Scher, H.I.11
-
21
-
-
77951518711
-
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate
-
Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI and de Bono JS: Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 28(9): 1489-1495. 2010.
-
(2010)
J Clin Oncol
, vol.28
, Issue.9
, pp. 1489-1495
-
-
Reid, A.H.1
Attard, G.2
Danila, D.C.3
Oommen, N.B.4
Olmos, D.5
Fong, P.C.6
Molife, L.R.7
Hunt, J.8
Messiou, C.9
Parker, C.10
Dearnaley, D.11
Swennenhuis, J.F.12
Terstappen, L.W.13
Lee, G.14
Kheoh, T.15
Molina, A.16
Ryan, C.J.17
Small, E.18
Scher, H.I.19
De Bono, J.S.20
more..
-
22
-
-
77951591066
-
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer
-
Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M and Scher HI: Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 28(9): 1496-501, 2010.
-
(2010)
J Clin Oncol
, vol.28
, Issue.9
, pp. 1496-1501
-
-
Danila, D.C.1
Morris, M.J.2
De Bono, J.S.3
Ryan, C.J.4
Denmeade, S.R.5
Smith, M.R.6
Taplin, M.E.7
Bubley, G.J.8
Kheoh, T.9
Haqq, C.10
Molina, A.11
Anand, A.12
Koscuiszka, M.13
Larson, S.M.14
Schwartz, L.H.15
Fleisher, M.16
Scher, H.I.17
-
23
-
-
77952105685
-
Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study
-
Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL; Prostate Cancer Foundation Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375(9724): 1437-1446, 2010.
-
(2010)
Lancet
, vol.375
, Issue.9724
, pp. 1437-1446
-
-
Scher, H.I.1
Beer, T.M.2
Higano, C.S.3
Anand, A.4
Taplin, M.E.5
Efstathiou, E.6
Rathkopf, D.7
Shelkey, J.8
Yu, E.Y.9
Alumkal, J.10
Hung, D.11
Hirmand, M.12
Seely, L.13
Morris, M.J.14
Danila, D.C.15
Humm, J.16
Larson, S.17
Fleisher, M.18
Sawyers, C.L.19
Prostate Cancer Foundation20
Department of Defense Prostate Cancer Clinical Trials Consortium21
more..
|